Dr Jeffery Matous at ASH 2014: Brentuximab vedotin and autologous stem cell transplant in Hodgkin lymphoma

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses results of recent clinical studies of brentuximab vedotin (BV) in Hodgkin lymphoma (HL).

The phase III AETHERA trial is a randomised, double-blind, placebo-controlled study of BV in the treatment of patients at risk of progression following autologous stem cell transplant (ASCT) for HL. A single-arm, two-stage, open-label, phase I/II study is evaluating the safety and efficacy of BV in combination with bendamustine for the treatment of HL in first relapse or refractory patients, prior to ASCT.